Carmot Therapeutics Initiates Phase 1 Trial to Treat Type 2 Diabetes

Carmot Therapeutics announced today the initiation of a clinical trial for the treatment of type 2 diabetes with CT-868, a dual modulator of the GLP-1 and GIP incretin receptors. The Phase 1 trial will evaluate the safety, tolerability, pharmacokinetics, https://www.businesswire.com/news/home/20181219005180/en/Carmot-Therapeutics-Initiates-Phase-1-Trial-Treat